CORT 📈 Corcept Therapeutics - Overview

Corcept Therapeutics Incorporated is a pharmaceutical company that focuses on the discovery, development, and commercialization of treatments for complex, severe disorders. The company's primary area of expertise lies in addressing endocrinologic, oncologic, metabolic, and neurologic conditions, with a specific emphasis on conditions related to cortisol excess and other hormonal imbalances. Its lead product, Korlym, is a medication designed to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, particularly those with type 2 diabetes mellitus or glucose intolerance who are not suitable candidates for surgery or have failed surgical interventions.

Corcept Therapeutics has a robust pipeline of investigational drugs, including relacorilant, which is currently in a phase III clinical trial for the treatment of Cushing's syndrome. The company is also exploring the potential of relacorilant in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian tumors, with this combination undergoing phase III clinical trials. Additionally, Corcept is investigating the use of its compounds in the treatment of adrenal cancer, cortisol excess, and prostate cancer, with these programs at various stages of clinical development, including phase I and phase II trials.

Furthermore, the company is expanding its therapeutic scope to include treatments for neurologic and metabolic disorders. For instance, dazucorilant is being developed for the treatment of amyotrophic lateral sclerosis (ALS) and is currently in phase II clinical trials. Miricorilant is another compound in development, which is in phase IIb trials for the treatment of nonalcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage due to fat accumulation. The company is also exploring the potential of its compounds in addressing antipsychotic-induced weight gain, with a phase I trial underway.

Established in 1998, Corcept Therapeutics Incorporated is headquartered in Menlo Park, California, and its common stock is listed on the NASDAQ under the ticker symbol CORT. The company operates within the pharmaceuticals sub-industry and is identified by the ISIN code US2183521028. With a strong foundation in endocrinology and a growing pipeline of investigational treatments, Corcept Therapeutics is positioned to address significant unmet medical needs across a range of severe and complex disorders.